ACS Creates $1 Billion Nationwide Organization, Taking Fiduciary Control From 12 Divisions
With No Budget in Sight, NCI Takes Careful Steps; Success Rate Last Year Was 14 percent
FDA Revokes Avastin’s Accelerated Approval In Metastatic Breast Cancer Indication
Industry Groups Lobby for Lower Standards for FDA Approval
Trending Stories
- DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - Kennedy announces massive cuts, centralization at HHS—NCI and FDA hit
Also this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology - What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - Jonathan Friedberg tells us how he built a cancer center in an underserved area of New York State
- Breast cancer activists in the 90s got DOD to fund cancer research—now that program has been gutted
- The insinuation that AstroTurf causes GBM has no basis in science
The Philadelphia Inquirer series does disservice to brain tumor community